# FluGen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/flugen

- Industry: Pharmaceuticals
- Headquarters: Madison, US
- Website: www.flugen.com
- Total disclosed funding: $9.4M
- Latest round: Series A (Aug 10, 2015)
- Investors on record: 4

## About

FluGen, Inc. is a biotechnology company focused on developing innovative vaccines for influenza and respiratory diseases, addressing significant public health challenges with its advanced vaccine platforms.Founded in 2007 and headquartered in Madison, US, FluGen, Inc. specializes in flu vaccine development, notably the M2SR vaccine platform. The company has engaged in 10 deals, with a pivotal Venture Debt funding round in November 2018, raising USD 5.58 mn, bringing the total amount raised to USD 5.50 mn. The CEO, Paul Radspinner, leads the company based on his extensive background in the biotech sector.FluGen, Inc. primarily offers the M2SR Vaccine Platform, designed for the prevention of influenza and respiratory diseases. The flagship product, M2SR, is an intranasal, supra-seasonal flu vaccine that promotes a comprehensive immune response. It effectively addresses critical unmet needs in flu prevention, providing consistent efficacy against annual virus drift and shedding. The M2SR vaccine is supported by clinical evidence of its effectiveness and targets diverse end-users, including both pediatric and adult populations, in key markets facing public health challenges from seasonal influenza and other respiratory viruses.FluGen, Inc. generates revenue primarily through partnerships and collaborations with healthcare organizations and institutions involved in vaccine distribution and public health initiatives. The business model focuses on B2B transactions, facilitating the deployment of the M2SR vaccine in clinical settings, which may include arrangements with governmental health agencies and private healthcare providers. The revenue trajectory will be influenced by the uptake of the M2SR vaccine in various healthcare markets and the advancements in ongoing clinical trials.FluGen, Inc. plans to leverage recent funding from the USD 5.58 mn Venture Debt round to support the development of its M2SR vaccine and explore new markets. The company aims to expand its presence in North America and Europe by enhancing distribution networks and forming additional partnerships with health agencies by the end of 2023. Continued focus on clinical trial advancements will also be critical to its growth strategy, positioning the M2SR vaccine as a key solution against influenza and respiratory diseases.

## Funding rounds

- Series A, Aug 10, 2015, $9.4M — Venture Investors, State of Wisconsin Investment Board, Knox LLC, WARF Ventures

## Investors

- Venture Investors — Series A
- State of Wisconsin Investment Board — Series A
- Knox LLC — Series A
- WARF Ventures (https://capitalatlas.ai/funds/warf-ventures) — Series A